|
African Journal of Health Sciences
The Kenya Medical Research Institute (KEMRI)
ISSN: 1022-9272
Vol. 14, Num. 3-4, 2007, pp. 212-215
|
African Journal of Health Sciences, Vol. 14, No. 3-4, Jul-Dec, 2007, pp. 212-215
Baseline CD4
lymphocyte count among HIV patients in Kano, Northern Nigeria
Emmanuel E. Nwokedi,* Ochicha Ochicha, Aminu Z. Mohammed and
Nasiru M. Saddiq
Departments of Medical Microbiology & Pathology*, Bayero University
/ Aminu Kano Teaching Hospital, Kano, Nigeria; P.M.B.
3452 Kano, Nigeria
*Address for
Correspondence: Dr E.E. Nwokedi; Department of Microbiology / Parasitology
Aminu Kano Teaching Hospital; P.M.B. 3452 Kano, Nigeria
Code Number: jh07030
SUMMARY
HIV causes immunodeficiency by infection, lyses and
depletion of CD4 T-lymphocytes; hence CD4 count has become a valuable indicator
of immune function in the management of HIV infection. Consequently, we
evaluated baseline CD4 counts of 500 HIV seropsitive adults in a government
sponsored anti-retroviral treatment (ART) scheme at our centre, for the purpose
of monitoring subsequent response to anti-retrovirals. The overwhelming
majority (92%) of our patients were within the sexually active, 3rd to 5th
decade age group, and the mean CD4 count was 302 cells/µl. Half of our patients
(251 cases) had AIDS as defined by CD4 count <200 cells/µl and 72% had CD4
count <350 cells/µl, the WHO recommended criterion for instituting ART. In
general our HIV seropositives had CD4 counts comparable to other studies here
in Nigeria and the West African sub-region, but higher than in East Africa and Europe. In view of the well documented higher CD4 count of West Africans, it might be
necessary to upwardly review the WHO recommended 350 cells/µl benchmark for
instituting ART.
Introduction
Using
CD4 and CXCR4 cell surface molecules as receptor and co-receptor respectively;
HIV infects T-helper lymphocytes, replicates within them and lyses the cells as
the replicated virions are released extracellularly to infect yet other CD4
cells [1,2]. Consequently CD4+ T-helper lymphocytes are gradually depleted and
the immune system crippled [1,2]. Since CD4 lymphocytes are the most crucial
cells in adaptive immunity that direct and coordinate the functions of other
adaptive immune cells (B-lymphocytes, CD8 lymphocytes & monocytes /
macrophages), the devastating effect of HIV on the immune system is not
surprising.
Given that HIV induced immunodeficiency is largely due to infection and gradual
depletion of CD4+ T-helper cells, CD4 count has become a useful indicator of
immune function in infected patients. Hence CD4 count along with viral load
(HIV-RNA) is invaluable in management of HIV infection, particularly in
monitoring response to anti-retroviral therapy (ART) [3, 4, 5]. CD4 count is
said to be the most reliable prognostic indicator of immune response to therapy
[3, 6, 7], and is thus a major criterion in the CDC/WHO classification of HIV infection,
which is widely used to categorize patients for clinical management [8]. With
the introduction of heavily subsidized ART by the Nigerian Federal government
in several tertiary health institutions around the country including Aminu
Kano Teaching Hospital here in Kano it became necessary to monitor the CD4
lymphocyte counts of HIV patients managed under the subsidized ART scheme. This
study endeavours to appraise the baseline CD4 profile of HIV seropositive
patients at the commencement of anti-retroviral treatment.
Materials and Methods
Six
hundred adults were recruited for this study 100 healthy controls and 500 HIV
seropositive patients. The HIV seropositives were recruited from patients
attending the HIV/AIDS clinic at Aminu Kano Teaching hospital, Kano over a 15 month period from April 2002 to June 2003. Our healthy controls were
randomly selected seronegative students of a local tertiary educational
institution and seronegative pregnant women attending ante-natal clinc at the
teaching hospital.
Children were excluded from this study because initially the Federal Ministry
of Health, subsidized ART scheme was only targeted at adults. Laboratory
diagnosis of HIV infection was established by double ELISA technique (Capillus
& Immunocomb), and CD4 count was estimated manually by Dynal Enumeration
Technique. The CD4 lymphocytes were counted prior to commencement of ART
and at six month intervals thereafter. Only the baseline data at the beginning
of therapy was used for this study.
Results
Of
the 500HIV positive patients, 307 were males and 193 were females (M: F =
1.6:1). Although the age range was quite wide (18-64 years), most patients
(92%) fell within the 3rd to 5th decades. About half of the patients (251cases)
had AIDS as defined by CD4 count below 200 cells/µl [8]. Seventy two percent of
our study subjects (359 cases) had CD4 count <350 cells/µl the WHO
laboratory criteria for instituting ART in a resource limited setting [9,10]
such as here in Northern Nigeria. Only 9.6% (48 cases) had normal CD4 counts
i.e. >600 cells/µl. The mean CD4 count of HIV seropsitive individuals in
this study was 302 cells/µl. The healthy controls were aged between 18 & 38
years and had CD4 counts ranging from 697 to 1829 cells/µl with a mean of 1295
cells/µl.
Figure 1: age distribution of CD4 lymphocyte count among HIV patients in
Kano
CD4 count
Cells/µl |
< 20 years |
20-29
years |
30-39
years |
40-49
years |
50-59
years |
> 60 years |
Total |
< 100 |
- |
17 |
47 |
30 |
3 |
- |
97 |
100 199 |
1 |
29 |
64 |
29 |
8 |
2 |
133 |
200 299 |
1 |
27 |
42 |
25 |
3 |
1 |
99 |
300 399 |
1 |
16 |
26 |
13 |
1 |
- |
57 |
400 499 |
2 |
11 |
12 |
9 |
- |
- |
34 |
500 599 |
1 |
6 |
18 |
5 |
2 |
- |
32 |
600 699 |
- |
- |
8 |
- |
1 |
- |
9 |
700 799 |
1 |
4 |
1 |
- |
1 |
- |
7 |
800 899 |
- |
1 |
4 |
- |
2 |
- |
7 |
900 999 |
- |
2 |
1 |
1 |
- |
- |
4 |
> 1000 |
1 |
4 |
9 |
5 |
1 |
- |
20 |
Total |
8 |
117 |
232 |
118 |
22 |
3 |
500 |
Discussion
Most
(92%) of the HIV positive patients in this study were within the 3rd to 5th
decades age bracket, which is not surprising in view of the fact that these are
the most sexually active age group heterosexual intercourse being the major
mode of transmission in Africa [11]. However since children in the first two
decades were largely excluded from this study, the age profile is obviously
skewed in favour of adults, and accentuates the prominence of the sexually
active age group. In Jos, a neighbouring northern Nigerian city, similar study
reported this sexually active 3rd to 5th decade age group comprised 46% (AIDS)
and 59% (HIV positive) [12]. The lower proportion of the sexually active age
group in their study could be partly explained by the inclusion of
children. Males outnumbered females (M: F = 1.6:1) in this series
comprising 61.4% of our HIV seropositives. This is at variance with the
well-documented fact that women are biologically and socially more vulnerable
to HIV infection, particularly in the third world [11]. Socio-cultural restrictions
on Muslim women here in Nigerias Islamic north adversely affect hospital
attendance and may explain the lower proportion of women in our study.
About half (50%) of our HIV patients had AIDS as defined by CD4 count < 200
cells/µl which is comparable to 54% in Jos, another northern Nigerian city
[12]. Obviously the major reason for this high proportion of AIDS is because
of late presentation, largely due to the fact that we are yet to imbibe the
culture of voluntary screening for early detection and treatment. Fear of
stigmatization, lack of awareness and inadequate trained counseling personnel
are some of the factors militating against voluntary screening. Many patients
only seek medical attention and are diagnosed when HIV infection becomes
complicated by AIDS defining illnesses. Blacks in South Africa similarly
presented late with advanced disease [13].
The mean CD4 count of our HIV patients was 302 cells/µl, which is higher than
270 cells/µl in the UK [14]. A comparative study between HIV
patients in France and Francophone West Africa similarly documented higher CD4
counts in West Africans than in Europe [15]. The mean CD4 count for our healthy
controls 1295 cells/µl - was also higher than the normal mean of 800 to1050
cells/µl in the Western world [6,16]. In Switzerland normal CD4 count was as
low as 309 cells/µl [17]. Njoku et al in Jos, also reported higher mean CD4
counts in healthy controls and HIV patients than in the Western world [12].
They attributed this physiologic lymphocytosis in Africans to common
infections in our environment. This hypothesis is somewhat undermined by
reports from East Africa which document lower CD4 count than in the Western
world [18,19]. It thus appears that this physiologic lymphocytosis is
peculiar to West Africans, which suggests that genetic factors might also be
involved rather than just microbial infections from the environment.
The obvious implication of higher West African CD4 count in HIV management is
that the widely adopted WHO/CDC classification of HIV infection based on CD4
count may need to be modified for West Africans. Consequently Anglaret et a
[15] propose threshold values of 250 and 700 cells/µl rather than the CDC/WHO
recommended 200 and 500 cells/µl for laboratory categorization of HIV
infection. Thus it might be necessary to institute ART at higher CD4 counts of
about 400-500 cells/µl in West Africa rather than the present 350 cells/µl.
With the current benchmark of 350 cells/µl, over 70% of our patients already
qualify for ART. An upward review of the benchmark translates to many more HIV
seropositives requiring ART, which would strain the lean financial resources of
the subsidized ART scheme.
References
- Murray PR, Baron EJ, Jorgensen JH
et al. HIV in: Manual of clinical microbiology. ASM press, Washington DC.
2000. p1253-1260.
- Cotran RS, Kumar V, and Collins T.
AIDS in: Robbins pathologic basis of disease. WB Saunders Philadelphia.
1999. p236-242.
- Mellors JW, Munoz A, Giorgi JV
Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R,
Phair JP, Rinaldo CRJr. Plasma viral load & CD4+ lymphocyte as prognostic
markers of HIV-1 infection. Annals of Internal Medicine 1997; 126:946-954.
- Lundgren JD, Mocroft A, Gatell JM,
Ledergerber B, DArminio Monforte A, Hermans P, Goebel FD, Blaxhult A, Kirk O,
Phillips AN, EUROSIDA Study Group. A clinically prognostic scoring system for
patients receiving HAART: results from EUROSIDA study. Journal of Infectious
Diseases. 2002; 185:178-187.
- Ghani AC; de Wolf F;
Ferguson NM; Donnelly CA; Coutinho R; Miedema F; Goudsmit J; Anderson RM.
Surrogate markers for disease progression in treated HIV infection. Journal
of Acquired Immune Deficiency Syndrome. 2001. 28:226-231.
- Bartlett JG, Gallant JE. CD4 cell
count in Medical management of HIV infection. John Hopkins Medicine,
Baltimore. 2004. p18-20.
- Chene G, Sterne JA, May M,
Costagliola D, Lodergerber B, Phillips AN, Dabis F, Lundgren J, DArminio
Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Lepon C, Staszowski S, Gill
J, Fatkenheuer G, Egger ME, Antiretroviral Therapy Cohort Collaboration.
Prognostic importance of initial response in HIV-1 infected patients starting
potent anti-retroviral therapy: Analysis of prospective studies. Lancet 2003; 362:679-686.
- Center for disease control &
prevention. 1993 Revised classification system and expanded surveillance
definition for AIDS. MMWR. 1992; 41: 2-4
- World Health Organization (WHO).
Scaling up antiretroviral therapy in resource-limited settings: treatment
guidelines for a public health approach. 2003 revision. Geneva: WHO; 2004.
68p
- Federal Ministry of Health. Guidelines
for the use of Anti-retroviral drugs in Nigeria. FMOH, Abuja. 2003. p35.
- UNAIDS: HIV Epidemic A global
update. UNITED NATIONS World AIDS day report. Health Millions.
1998; 24: 3-5.
- Njoku MO, Sirisena ND, Idoko JA,
Jelpe D. CD4+ T-lymphocyte counts in patients with HIV-1 and healthy population
in Jos, Nigeria. Nigerian Postgraduate Medical Journal. 2003; 10:135-139.
- Burns F, Fakova A, Copas A. Africans
with HIV present with advanced disease in the era of HAART. International Conference on AIDS. 2000; Jul 9-14; 13:68 (abstract no.
LbPeE7131).
- Saul J, Erwin J, Bruce JC, Peters
B. Ethnic and demographic variations in HIV / AIDS presentation at two London
referral centers 1995-9. Sexually Transmitted Infections. 2000; 76:215.
- Anglaret X, Diagbouga S, Mortier
E, Meda N, Verge-Valette V, Sylla-Koko F, Cousens S, Laruche G, Ledru E, Bonard
D, Dabis F, Vande Perre P. CD4+ T-lymphocyte counts in HIV infections: Are
European standards applicable to African patients? Journal of AIDS &
Human Retrovirology. 1997; 14:361-363.
- Laurence J. T-cell subsets in
health, infectious disease and idiopathic CD4+ T-lymphocytopenia. Annals of
Internal Medicine. 1993; 119:55-62.
- Bisset LR, Lung TL, Kaelin M,
Ludwig E, Dubs RW. Reference values for peripheral blood lymphocytes phenotypes
applicable to the healthy adult population in Switzerland. European Journal
of Haematology. 2004; 72:203-212.
- Urassa WK, Mbena EM, Swai AB,
Gaines H, Mhalu FS, Biberfeld G. Lymphocyte subset enumeration in HIV
seronegative and HIV-1 seropositive adults in Dar es Salaam Tanzania:
determination of reference values in males and females and comparison of two
flow cytometric methods. Journal of Immunological Methods. 2003; 277:65-74.
- Wolday D, Tsegaye A, Messele T.
Low absolute CD4 count in Ethiopians. Ethiopian Medical Journal. 2002; 40
suppl 1: 11-16.
© Copyright 2007 - African Forum for Health Sciences
|